{"disease":{"id":"t-cell-malignancies","name":"t cell malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00585195","title":"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":596,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04277637","title":"Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":437,"lead_sponsor_name":"BeOne Medicines","has_results":false},{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT06576102","title":"Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":204,"lead_sponsor_name":"Maddalena Giannella","has_results":false},{"nct_id":"NCT01010217","title":"Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02325739","title":"FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":172,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07390838","title":"A Study of SH009 Injection in Patients With Advanced Solid Tumors.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","has_results":false},{"nct_id":"NCT05724121","title":"Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax","phase":"","overall_status":"RECRUITING","enrollment_count":135,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT02825836","title":"Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"Telios Pharma, Inc.","has_results":false},{"nct_id":"NCT03932331","title":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":105,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04430530","title":"4SCAR-T Therapy Post CD19-targeted Immunotherapy","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT05665530","title":"A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT02561988","title":"(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT07493174","title":"Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":86,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT04014205","title":"A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":81,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT06316427","title":"Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT04865458","title":"A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Sunshine Lake Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT06351527","title":"Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"InnoCare Pharma Inc.","has_results":false},{"nct_id":"NCT05780034","title":"A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Accutar Biotechnology Inc","has_results":false},{"nct_id":"NCT04989387","title":"Study of INCA 0186 in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT02194868","title":"Immunoregulatory T Lymphocytes Subtypes and Haematopoietic Stem Cell Transplantation (HSCT)","phase":"","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04689308","title":"This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"Minghui Pharmaceutical (Shanghai) LTD","has_results":false},{"nct_id":"NCT04172246","title":"Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT06316856","title":"CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT07070323","title":"A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT03198650","title":"A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07002112","title":"The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT02457559","title":"Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT07345728","title":"Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies","phase":"NA","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Donghua Zhang","has_results":false},{"nct_id":"NCT05336409","title":"A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":28,"lead_sponsor_name":"Century Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04447027","title":"Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02722668","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT04943016","title":"CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT05645601","title":"CAR-NK Targeted CD19 for r/r B-cell Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":12,"lead_sponsor_name":"Affiliated Hospital to Academy of Military Medical Sciences","has_results":false},{"nct_id":"NCT07309900","title":"IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT06732492","title":"RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05588440","title":"A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Oncternal Therapeutics, Inc","has_results":true},{"nct_id":"NCT07240974","title":"Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":6,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05694364","title":"Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false},{"nct_id":"NCT02991898","title":"Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":true},{"nct_id":"NCT04428918","title":"Biospecimen Procurement for Immunological Landscape Studies Following Hematopoietic Cell Transplantation","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05359692","title":"INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Incyte Biosciences International Sàrl","has_results":false}],"total":42},"guidelines":[],"source":"Drug Landscape verified database"}